In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
BioCryst Pharmaceuticals's net current asset value per share for the quarter that ended in Mar. 2026 was $-2.54.
The historical rank and industry rank for BioCryst Pharmaceuticals's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of BioCryst Pharmaceuticals was 286.50. The lowest was 6.09. And the median was 30.00.
BCRX's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.71 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BioCryst Pharmaceuticals (NAS:BCRX) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
BioCryst Pharmaceuticals Net Current Asset Value Related Terms
BioCryst Pharmaceuticals Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for BioCryst Pharmaceuticals's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals Net Current Asset Value Chart
BCRX vs SUPN, PBH, AMLX: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCryst Pharmaceuticals Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where BioCryst Pharmaceuticals's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $-2.54 mean?
BioCryst Pharmaceuticals (BCRX) has a Net Current Asset Value of $-2.54 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BioCryst Pharmaceuticals and its competitors. Over the past decade, BioCryst Pharmaceuticals' Net Current Asset Value has ranged from 6.09 to 286.50. According to the industry distribution chart, BioCryst Pharmaceuticals ranks #999999 out of 613 companies in the Drug Manufacturers industry.
Is BioCryst Pharmaceuticals' Net Current Asset Value too high?
BioCryst Pharmaceuticals' current Net Current Asset Value is $-2.54. Over the past 10 years, this metric has ranged from a low of 6.09 to a high of 286.50. Based on the distribution chart, BioCryst Pharmaceuticals ranks #999999 out of 613 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioCryst Pharmaceuticals has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Net Current Asset Value compare to SUPN and PBH?
According to the Drug Manufacturers industry distribution chart, BioCryst Pharmaceuticals ranks #999999 out of 613 companies for Net Current Asset Value. This places BioCryst Pharmaceuticals in the lower half of its industry. The industry median Net Current Asset Value is 5.71. Historically, BioCryst Pharmaceuticals' own Net Current Asset Value has ranged from 6.09 to 286.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.71, based on 613 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BioCryst Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCryst Pharmaceuticals's current Net Current Asset Value is $-2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.62, compared to a current price of $9.84 — trading 22% below its estimated fair value. The current Net Current Asset Value is $-2.54. BioCryst Pharmaceuticals' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current Net Current Asset Value is $-2.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued.
The current stock price of $9.84 is trading 22% below its estimated GF Value™ of $12.62.
GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BCRX:
Net Current Asset Value: $-2.54
GF Value™: $12.62 vs. price of $9.84 (22% below fair value)
No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
66GF Score
Get the complete analysis for BCRX
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCRX has been successfully added to your 
